An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 471 participants.

Also called NCT01560637

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 471 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01560637
Other papers using this trial's data
  • Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension Advances in therapy, 2024-02 DOI, PubMed 38055186, PMC10838815 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, India, Israel, Italy, Mexico, Netherlands, Poland, Singapore, South Korea, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01560637. Allocation not applicable; no masking; primary purpose treatment. Start 2013-09-11 (actual); primary completion 2021-08-12 (actual). Results posted on 2022-06-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
UT-15C (treprostinil diolamine)
Lead sponsor
United Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01560637
Content hash
b30a07517fbd221366b48e57c350dccf0815b5a6b19a5fcbe256c9a8b6032dfc